LENZ Earnings & Financial Statements
LENZ Therapeutics, Inc.
$3.65
+$0.12(+3.26%)
37
Overall
60
Value
18
Tech
34
Quality
Market Cap
$114.53M
Volume
625.76K
52W Range
$3.35 - $42.98
Target Price
$22.00
LENZ earnings and financial statements: LENZ Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
LENZ Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $19.09M | - | - | $15.00M | - |
| Cost of revenue | $418.0K | - | - | - | - |
| Operating income | -$91.14M | -$58.61M | -$72.43M | -$105.64M | -$60.44M |
| EBITDA | -$81.34M | -$49.71M | -$70.13M | -$9.71M | -$70.03M |
| Net income | -$82.13M | -$49.77M | -$69.97M | -$10.81M | -$70.76M |
| EPS (diluted) | $-2.85 | $-2.34 | $-15.33 | $-12.88 | $-17.15 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $305.88M | $215.30M | $70.38M | $321.90M | $401.99M |
| Total liabilities | $21.54M | $11.22M | $19.70M | $25.61M | $17.94M |
| Shareholders’ equity | $284.34M | $204.08M | -$92.71M | $296.29M | $384.05M |
| Cash and equivalents | $25.18M | $20.16M | $35.14M | $47.73M | $376.98M |
| Long-term debt | $350.0K | $814.0K | $192.0K | $1.75M | $5.79M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$69.17M | -$59.39M | -$60.38M | -$4.09M | -$5.39M |
| Capital expenditure | -$827.0K | -$468.0K | -$30.0K | -$37.0K | -$9.0K |
| Free cash flow | -$70.00M | -$59.86M | -$60.41M | -$4.13M | -$5.40M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | LENZ | $3.65 | +3.3% | 625.76K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |